Sales of the Covid-19 vaccine developed by Pfizer and BioNTech could reach up to $15 billion in 2021 and go higher if Pfizer signs additional supply contracts, Pfizer said Tuesday.

The projections came as Pfizer projected full-year 2021 sales of between $59.4 billion and $61.4 billion, meaning that about one-fourth of estimated total sales will come from the Covid-19 vaccine.

The forecast reflects “a continued recovery in macroeconomic and healthcare activity throughout 2021 as more of the population becomes vaccinated against Covid-19,” Pfizer said.
[ad]
“These assumptions are guided by the trajectory of current infection rates in many parts of the world and the expected timeline for broad access to effective vaccines.”

Pfizer reported fourth-quarter net income of $594 million, compared with a loss of $337 million in the year-ago period.

For all of 2020, Pfizer reported profits of $9.6 billion, down 41.4 percent from 2019, with revenues up two percent to $41.9 billion.
[ad]
Pfizer’s fourth-quarter revenues included $154 million in sales of the Covid-19 vaccine.

The vaccine began winning approval from authorities late last year. Pfizer said it expects it could potentially deliver up to 2 billion doses in 2021 based on several factors, including adding more suppliers and contract manufacturers.

Shares of Pfizer rose 0.5 percent to $35.94 in pre-market trading.

[ad]